Innovating Renal Care Through Smarter, Safer MedTech

NATION BUILDER Of HEALTHCARE 2026

> Global-quality healthcare innovation can be conceived, engineered and manufactured in India and taken to the world.



RAVI VAZIRANI

Director
Atlantic Bio Medical Pvt. Ltd.

Vision & Leadership

For me, the future of healthcare is about making high-quality, advanced care more accessible, reliable and sustainable. Over the past four decades, Atlantic Biomedical has built its journey around a very specific need—improving renal care and making dialysis safer and more efficient. This experience has given us a strong foundation in understanding the evolving needs of healthcare professionals and patients.

I have always believed that Indian companies can do much more than serve the domestic market. We can develop and manufacture solutions that meet global standards and contribute meaningfully to healthcare systems worldwide. Our focus is therefore on combining strong engineering, manufacturing discipline, quality and an understanding of real clinical needs to create solutions that healthcare professionals can trust.

Our manufacturing facilities are ISO 13485 certified, and our products have EU CE Compliance Certification (CE 0123) from TÜV SÜD, Munich, Germany. For us, these are not simply credentials; they reflect the

ATLANTIC
SHAPING TOMORROW'S DIALYSIS CARE.

quality, consistency and discipline we aim to maintain throughout every stage of product development and manufacturing.

Innovation & Technology

Innovation remains at the heart of our growth strategy. I see innovation as identifying everyday healthcare challenges and finding better, more effective solutions.

Our Renaclean+ Dialyzer Reprocessing System brings automation through testing, validation and documentation, improving consistency, efficiency and traceability. Our Rena Drycon Automatic Mixing System reduces manual intervention while providing online pH and conductivity monitoring.

Our Renacart bicarbonate cartridge and Renabag bicarbonate bag simplify bicarbonate preparation while reducing risks associated with microbial contamination, handling and storage. By enabling fresh bicarbonate preparation at the point of dialysis, they support safer and more efficient practices.
Going forward, we see significant opportunities in automation, connectivity and intelligent monitoring across dialysis infrastructure. Our approach is simple: technology must solve a genuine clinical or operational problem and create measurable value for healthcare providers and patients.

Impact & Patient Care

At the centre of everything we do is the patient. Dialysis is a recurring, life-sustaining treatment, so consistency, reliability and safety matter enormously.

Whether it is a concentrate, consumable, disinfectant or technology platform, our objective is to help hospitals and dialysis centres maintain safer processes while improving operational efficiency. Today, our solutions support dialysis care across India and international markets.

However, I believe our greatest responsibility is to never lose sight of the patient behind every product we manufacture. Every improvement in a process or reduction in manual intervention ultimately has a human impact. When we help a clinician work more safely or a dialysis centre operate more reliably, we contribute to a better treatment experience for the patient.

Growth & Industry Transformation

Healthcare is moving towards greater automation, tighter regulatory standards, digital traceability and more efficient models of care. At the same time, the growing burden of kidney disease will increase demand for safe, reliable and accessible dialysis.

I believe this creates a significant opportunity for Indian MedTech. Our strength is not only manufacturing, but our ability to engineer practical and cost-conscious solutions for diverse healthcare environments.
At Atlantic Biomedical, we are preparing by investing in technology, quality systems, product development and international regulatory readiness. Our growing presence in global markets, including Singapore, is an important milestone. Renacart and Renasol are registered in the Singapore Medical Device Register, strengthening our presence in a highly regulated healthcare market.

We are also expanding our distribution partnerships and international footprint across Asia, Africa and other emerging markets.

Future Vision

Over the next three to five years, my priority is to build Atlantic Biomedical into a stronger global MedTech organisation, with renal care at the heart of our expertise.

We will focus on expanding our product portfolio, investing in automation, technology and R&D, strengthening manufacturing capabilities and entering new international markets. We also want to deepen our relationships with clinicians, healthcare institutions and technology partners so that our innovation remains grounded in real clinical needs.

Ultimately, I want Atlantic Biomedical to demonstrate that global-quality healthcare innovation can be conceived, engineered and manufactured in India—and taken to the world.

For me, the next chapter is not simply about growing the company. It is about building on our legacy, embracing technology and creating a meaningful impact on renal care for the next generation of patients.